High-dose Dietary Zinc Promotes Prostate Intraepithelial Neoplasia in a Murine Tumor Induction Model
Overview
Authors
Affiliations
To evaluate the role of high-dose dietary zinc in the process of prostate malignancy, 60 Sprague-Dawley rats were randomly divided into four groups: tumor induction with carcinogen and hormone (group 1), oral zinc administration without tumor induction (group 2), oral zinc administration with tumor induction (group 3) and a control without zinc administration or tumor induction (group 4). Zinc was supplied orally in the form of zinc sulfate heptahydrate dissolved in drinking water to groups 2 and 3 for 20 weeks. Although the serum level of zinc measured at 20 weeks was maintained similarly in each group (P = 0.082), intraprostatic zinc concentrations were statistically different. Group 1 prostates contained the least amount of zinc in both the dorsolateral and ventral lobes at levels of 36.3 and 4.8 microg g(-1), respectively. However, in group 3, zinc levels increased in both lobes to 59.3 and 12.1 microg g(-1), respectively, comparable with that of group 4 (54.5 +/- 14.6 and 14.1 +/- 2.4 microg g(-1)). In spite of these increases in zinc concentration, the prevalence of prostate intraepithelial neoplasm was rather increased in group 3 (53.3% and 46.7%) compared with group 1 (33.3% and 33.3%) in both dorsolateral and ventral prostate lobes. Although prostate intraepithelial neoplasm did not develop in any prostate in group 4, zinc administration did induce prostate intraepithelial neoplasm in group 2 (46.7% and 40.0%). Thus, although high dietary zinc increased intraprostatic zinc concentrations, it promoted, instead of preventing, prostate intraepithelial neoplasm in a murine prostate malignancy induction model.
The association between zinc and prostate cancer development: A systematic review and meta-analysis.
Shahrokhi Nejad S, Golzari Z, Zangiabadian M, Salehi Amniyeh Khozani A, Ebrahimi R, Nejadghaderi S PLoS One. 2024; 19(3):e0299398.
PMID: 38507438 PMC: 10954196. DOI: 10.1371/journal.pone.0299398.
Zhang Y, Stopsack K, Wu K, Song M, Mucci L, Giovannucci E J Urol. 2022; 209(3):549-556.
PMID: 36453265 PMC: 10628854. DOI: 10.1097/JU.0000000000003080.
Zinc dysregulation in cancers and its potential as a therapeutic target.
Wang J, Zhao H, Xu Z, Cheng X Cancer Biol Med. 2020; 17(3):612-625.
PMID: 32944394 PMC: 7476080. DOI: 10.20892/j.issn.2095-3941.2020.0106.
Status and Interrelationship of Zinc, Copper, Iron, Calcium and Selenium in Prostate Cancer.
Singh B, Dwivedi S, Dhakad U, Murthy R, Choubey V, Goel A Indian J Clin Biochem. 2016; 31(1):50-6.
PMID: 26855488 PMC: 4731369. DOI: 10.1007/s12291-015-0497-x.